Cover storyCDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.
FDA lab analysis confirmed undisclosed dexamethasone in Qu Feng Huo Lou Dan, a pain-relief product sold online, raising label integrity and import surveillance concerns.
FDA issues second 2026 clinical hold on REGENXBIO's RGX-121 after spine MRI findings in five CAMPSIITE participants; BLA resubmission delayed indefinitely.
Janssen's Imaavy becomes the first FDA-approved treatment for wAIHA, setting a new regulatory and manufacturing benchmark for IV orphan biologics.
FDA's October 14 CDER webinar unpacks the January 2026 Bayesian methodology draft guidance, with direct implications for pediatric and rare disease trial submissions.
Latest edition
Interview20260622153015.png&w=1920&q=75&dpl=dpl_4mCM4LkTaakSXHxN4EsrYb1NmZRR)
Interview
Interview
Podcast
Sep 28
Nov 18
Feb 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.
Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
20260804110923.webp&w=1920&q=75&dpl=dpl_4mCM4LkTaakSXHxN4EsrYb1NmZRR)
